# OnCo record alcanza (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/alcanza/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "alcanza", "NCT01578499" ;
  schema:name "ALCANZA"@en ;
  schema:description "ALCANZA showed that brentuximab vedotin produced lasting improvement in the skin disease of far more people with CD30-positive cutaneous T-cell lymphoma than the standard tablets methotrexate or bexarotene."@en ;
  schema:url <https://onco.cc/trials/alcanza/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT01578499> ;
  onco:status "positive" ;
  onco:tag "subtype-trials" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/cutaneous-t-cell-lymphoma/>, <https://onco.cc/cancers/peripheral-t-cell-lymphoma/> ;
  onco:drugs <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/drugs/methotrexate/>, <https://onco.cc/drugs/bexarotene/> ;
  onco:companies <https://onco.cc/companies/takeda/>, <https://onco.cc/companies/pfizer/> ;
  onco:people <https://onco.cc/people/miles-prince/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-alcanza-brentuximab-vedotin-lancet-2017/> .